Bio-Rad Laboratories, Inc. (BIO-B) fundamentals score
Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Its Life Science segment and its Clinical Diagnostics segment generated approximately 40% and 60%, respectively, of its consolidated net sales for the year ended December 31, 2025.
Laboratory Analytical Instruments · Technology · Listed on NYSE
Overall: 5.0 out of 10, Mixed fundamentals
- Growth: 2.9/10
- Profitability: 3.8/10
- Financial health: 6.4/10
- Earnings quality: 8.7/10
- Valuation: 5.2/10
Scores are calculated from Bio-Rad Laboratories, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Technology stocks
- Micron Technology, Inc. (MU): 9.0/10
- Broadcom Inc. (AVGO): 8.9/10
- Logitech International S.A. (LOGI): 8.8/10
- Applovin Corporation (APP): 8.7/10
- Cirrus Logic, Inc. (CRUS): 8.7/10
- Hamilton Beach Brands Holding Company (HBB): 8.7/10
- Nerdwallet, Inc. (NRDS): 8.7/10
- Sandisk Corporation (SNDK): 8.7/10